Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imukin in Friedreich's Ataxia
NCT02035020Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- May 2013
- Primary completion
- Jul 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon gamma-1b in Friedreich ataxia (FA), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Change in cellular frataxin. Started May 2013; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT02035020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035020.